Interview: Fabrizio Greco – General Manager, AbbVie Italy
Fabrizio Greco, General Manager at AbbVie Italy, discusses the successful launch of the company’s new Hepatitis C treatment, how AbbVie is seeking to position itself as a partner to the…
Assogenerici (National Association of Generic Drugs Industries) is the official representative body of the industry of generic drugs and biosimilars in Italy, at the forefront in providing medicines at affordable prices and high quality for millions of citizens, helping to boost competition and innovation in the pharmaceutical sector. Associated companies both small and medium corporations for a wide range of drugs, by perfusion with Galen to traditional generics to cutting biosimilars, is distributed in pharmacies at public hospitals.
Established in 1993, Assogenerici represents over 50 pharmaceutical companies. The companies represented in Assogenerici provide 10,000 direct jobs in Italy over the important induced, highly specialized. Generic drugs generate over € 400 million of savings per year for the NHS and for patients, helping to ensure patient access to essential drugs releasing at the same time, valuable resources for new and expensive drug therapies.
Assogenerici plays an important advisory role in the Italian health sector. Assogenerici and its members are working with the Italian and European institutions to develop sustainable solutions for pharmaceutical care and to increase the competitive strength of Italy in the world pharmaceutical market.
Passeggiata di Ripetta, 22 – int. 1 – 00186 – Roma
Tel: +39.06.59.60.53.24
Fax: +39.06.54.31.323
E-mail: info@assogenerici.it
Posta Elettronica Certificata: assogenerici@pec.
Web: assogenerici.it
Fabrizio Greco, General Manager at AbbVie Italy, discusses the successful launch of the company’s new Hepatitis C treatment, how AbbVie is seeking to position itself as a partner to the…
Enrique Hausermann, CEO of EG, the Stada Group’s Italian affiliate for its generics business, discusses the progress the company has made since 2009, the promising areas for growth he sees…
CFCII’s Director provides us with an overview of the services offered to French and Italian companies by the Chamber, as well as her perceptions about investments between the two countries,…
Alberto Gugliemo, President of the Carlo Besta Institute in Milan, shares the changing perception of neurological diseases and neurological science in Italy, the nature of the institute’s collaboration with the…
Francesco Carugi, Managing Director at Grifols Italy, discusses the company’s presence in the plasma, plasma products and plasma diagnostics segments, the impact of the liberalization of the Italian plasma market on…
Dr. Giorgio Pisani, President and CEO of IBSA Italy, talks about his founding of the company in 2001 and its rapid growth in the market through a combination of organic…
Prof. Walter Ricciardi has just been appointed as the new president for the Italian National Institute of Health (ISS). He explains his priorities since taking office, the crucial role the…
Paolo Casati, general manager for Santen’s new affiliate in Italy, discusses the company’s first full year in the country, its aims for contributing to the global group’s 2020 Vision by…
Paolo Cionini, General Manager of LEO Pharma Italy, discusses the initial challenges of setting up the Italian affiliate during the height of the global financial crisis in 2011, the company’s…
Sofia Astrid Pennacchi, Secretary General of the British Chamber of Commerce for Italy, discusses the various services the Chamber offers its members, the positive effects the Expo has had on…
Giulio Volpe, Managing Director of Lundbeck’s Italian API’s production plant, discusses what is leading multinational companies to relocate their production to Italy, the value the Italian plant can offer the…
Enrico Allievi, President of the Italian OTC (Over The Counter) association, Assosalute, talks about the state of the OTC market in Italy, as well as the association’s role in creating…
See our Cookie Privacy Policy Here
